

#3 Pre Q

# Tanox, Inc.



10301 Stella Link  
Houston, TX 77025  
(713) 578-4000  
Fax: (713) 578-5002

FAX RECEIVED  
SEP 13 2002  
GROUP 1600

## FAX TRANSMISSION COVER SHEET

Date: September 12, 2002  
To: Examiner Wehbe  
Company: U.S. Patent & Trademark Office  
Fax: (703) 872-9306  
Sender: Cheryl A. Liljestrand

OFFICIAL

You should receive 3 page(s), including this cover. If you do not receive all pages, please call (713) 578-4182.

### Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 872-9306 on September 12, 2002 (Date)

Typed or printed name of person signing this certificate:  
Cheryl A. Liljestrand

Signature: Cheryl Liljestrand

only 16  
claims  
in D.I.

CONFIDENTIALITY NOTICE: The information contained in this facsimile is confidential and belongs to the sender. The information is intended for the use of the individual(s) or entity named above. Any disclosure, dissemination, copying, distribution, or unauthorized action in reliance upon this facsimile transmission is strictly prohibited. If you have received this communication in error, please be aware that these same obligations of confidentiality apply to you and immediately notify us by telephone. We will instruct you to return the original transmission documents to us via the U.S. Postal Service and we will reimburse you for the postage. Thank you.

PATENT  
ATTORNEY DOCKET NO.: TNX99-05-01  
Customer No.: 26839

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:  
Ruey S. LIOU

Serial No.: 09/991,470

Filed: November 20, 2001

For: Anti-IgE Gene Therapy

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**PRELIMINARY AMENDMENT**

Prior to the examination of this application on the merits, please enter the following amendments.

**IN THE CLAIMS:**

Please cancel claims 1-27 without prejudice or disclaimer to the subject matter contained therein.

Please add the following new claims:

Rule 1.126 17-28. (NEW) A method for inhibiting the binding of IgE to its high-affinity IgE receptor comprising administering a composition comprising a vector comprising a nucleic acid encoding an anti-IgE antibody or IgE binding fragment thereof.

A1 18-29. (NEW) A method of inducing a host cell to express an anti-IgE antibody that inhibits binding of human IgE to the high affinity IgE receptor